Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-dichloride Journal Article

  


Authors: Pandit-Taskar, N.; Larson, S. M.; Carrasquillo, J. A.
Article Title: Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-dichloride
Abstract: Metastatic disease to bone is commonly seen in the advanced stages of many cancers. The cardinal symptom, pain, is often the cause of significant morbidity and reduced quality of life. Treatment of bone pain includes nonsteroidal analgesics and opiates; however, long-term use of these drugs is commonly associated with significant side effects, and tolerance is common. External-beam radiation therapy is effective mainly in localized disease sites. Bone-targeting radiopharmaceuticals are beneficial in the management of patients with multiple metastatic lesions. This article focuses on the 3 most commonly used agents: the Food and Drug Administration-approved (89)Sr-chloride, (153)Sm-ethylenediaminetetramethylene phosphonic acid (EDTMP), and (223)Ra-dichloride. We will discuss the physical characteristics, clinical data, dosage, and administration of these agents, including optimal patient selection and toxicity associated with their use. These radioactive agents have proven efficacy in the treatment of painful osseous metastases from prostate cancer and breast cancer. Significant recent advances include use of these agents in combination with chemotherapy and the use of the α emitter (223)Ra-dichloride in prostate cancer, primarily to improve survival and skeletal related events. The review is presented in 2 parts. The first will discuss the characteristics and clinical use of (223)Ra-dichloride, and the second will discuss the β emitters (89)Sr and (153)Sm-EDTMP.
Keywords: bone neoplasms; bone tumor; review; antineoplastic agents; methodology; antineoplastic agent; radiopharmaceuticals; neoplasm; neoplasms; animal; animals; metastasis; pathology; oncology; bone; neoplasm metastasis; radiopharmaceutical agent; radiometry; radioisotope; radioisotopes; analgesia; organometallic compound; organometallic compounds; pain management; organophosphorus compounds; alpha radiation; alpha particles; organophosphorus compound; samarium ethylenediaminetetramethylenephosphonate; radium; strontium chloride; radionuclide therapy; strontium; radium chloride ra 223; humans; human
Journal Title: Journal of Nuclear Medicine
Volume: 55
Issue: 2
ISSN: 0161-5505
Publisher: Society of Nuclear Medicine  
Date Published: 2014-02-01
Start Page: 268
End Page: 274
Language: English
PUBMED: 24343987
PROVIDER: scopus
DOI: 10.2967/jnumed.112.112482
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-84897939554&partnerID=40&md5=b08e281c615437a06e6029227337eb4c
Notes: Export Date: 1 May 2014 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Neeta Pandit-Taskar
    342 Pandit-Taskar
  2. Jorge Carrasquillo
    140 Carrasquillo
  3. Steven M Larson
    958 Larson
Related MSK Work